Sanofi seeking partner to develop Oxford BioMedica's ophthalmology gene therapies

Oxford BioMedica plc (LSE:OXB) said Sanofi (Euronext:SAN; NASDAQ:SNY) will seek a partner to continue further development of two ophthalmology gene therapy programs that the pharma gained under a 2009 deal with Oxford BioMedica.

The products are StarGen (SAR422459), a LentiVector-based gene therapy expressing a corrected version of ABCA4, and UshStat (SAR 421869), a LentiVector-based gene therapy expressing a gene encoding MYO7A...